391
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Prevalence and Predictors of Multi-Drug Resistant Organisms Among Ambulatory Cancer Patients with Urinary Tract Infections

ORCID Icon, , , , ORCID Icon &
Pages 747-753 | Received 04 Sep 2022, Accepted 16 Dec 2022, Published online: 03 Feb 2023

References

  • Erdem I, Kara Ali R, Ardic E, et al. Community-acquired lower urinary tract infections: etiology, antimicrobial resistance, and treatment results in female patients. J Glob Infect Dis. 2018;10(3):129–132. doi:10.4103/jgid.jgid_86_17
  • Linhares I, Raposo T, Rodrigues A, et al. Incidence and diversity of antimicrobial multidrug resistance profiles of uropathogenic bacteria. Biomed Res Int. 2015;2015:354084. doi:10.1155/2015/354084
  • Hozzari A, Behzadi P, Kerishchi Khiabani P, et al. Clinical cases, drug resistance, and virulence genes profiling in Uropathogenic Escherichia coli. J Appl Genet. 2020;61(2):265–273. doi:10.1007/s13353-020-00542-y
  • Tenney J, Hudson N, Alnifaidy H, et al. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharma J. 2018;26(5):678–684. doi:10.1016/j.jsps.2018.02.023
  • Khonsari M, Behzadi P, Foroohi F. The prevalence of type 3 fimbriae in Uropathogenic Escherichia coli isolated from clinical urine samples. Meta Gene. 2021;28:100881. doi:10.1016/j.mgene.2021.100881
  • Behzadi P. Classical chaperone-usher (CU) adhesive fimbriome: uropathogenic Escherichia coli (UPEC) and urinary tract infections (UTIs). Folia Microbiol. 2020;65(1):45–65. doi:10.1007/s12223-019-00719-x
  • Behzadi P, García-Perdomo HA, Karpiński TM, et al. Metallo-ß-lactamases: a review. Mol Biol Rep. 2020;47(8):6281–6294. doi:10.1007/s11033-020-05651-9
  • Sarshar M, Behzadi P, Scribano D, Palamara AT, Ambrosi C. Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens. 2021;10(4):387. doi:10.3390/pathogens10040387
  • Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
  • Shrestha G, Wei X, Hann K, et al. Bacterial profile and antibiotic resistance among cancer patients with urinary tract infection in a National Tertiary Cancer Hospital of Nepal. Trop Med Infect Dis. 2021;6(2):49. doi:10.3390/tropicalmed6020049
  • Katayama H, Tabata M, Kubo T, et al. Demand for weekend outpatient chemotherapy among patients with cancer in Japan. Support Care Cancer. 2021;29:1287–1291. doi:10.1007/s00520-020-05575-x
  • Walker E, Lyman A, Gupta K, et al. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis. 2016;63(7):9605. doi:10.1093/cid/ciw396
  • Behzadi P, Urbán E, Matuz M, et al. The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol. 2021;1323:35–69.
  • Sime WT, Biazin H, Zeleke TA, et al. Urinary tract infection in cancer patients and antimicrobial susceptibility of isolates in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. PLoS One. 2020;15(12):e0243474. doi:10.1371/journal.pone.0243474
  • Ahmadi M, Ranjbar R, Behzadi P, et al. Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella Pneumoniae. Expert Rev Anti Infect Ther. 2022;20(3):463–472. doi:10.1080/14787210.2022.1990040
  • Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol. 2010;51(7):492–497. doi:10.4111/kju.2010.51.7.492
  • Nanayakkara AK, Boucher HW, Fowler JVG, et al. Antibiotic resistance in the patient with cancer: escalating challenges and paths forward. CA Cancer J Clin. 2021;71(6):488–504. 11. doi:10.3322/caac.21697
  • Calbo E, Romaní V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006;57(4):780–783. doi:10.1093/jac/dkl035
  • Behzadi P, Behzadi E. The microbial agents of urinary tract infections at central laboratory of Dr. Shariati Hospital, Tehran, Iran. Turk Klin Tip Bilim. 2008;28(4):445–449.
  • Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11(11):1756287219832172. doi:10.1177/1756287219832172
  • Sarshar M, Behzadi P, Ambrosi C, et al. FimH and anti-adhesive therapeutics: a disarming strategy against uropathogens. Antibiotics. 2020;9(7):397. doi:10.3390/antibiotics9070397
  • Kalluru S, Eggers S, Barker A, et al. Risk factors for infection with multidrug-resistant organisms in Haryana, India. Am J Infect Control. 2018;46(3):341–345. doi:10.1016/j.ajic.2017.08.021